The European Association for the Study of Obesity (EASO) has called for GLP-1 agonists from Novo Nordisk and Eli Lilly to be used first-line for people with obesity and most of its complications. New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback